Eli Lilly’s Zepbound single-dose vials will expand access to more patients: Mizuho’s Jared Holz

August 27, 2024
Eli Lilly’s Zepbound single-dose vials will expand access to more patients: Mizuho’s Jared HolzEli Lilly’s Zepbound single-dose vials will expand access to more patients: Mizuho’s Jared Holz

Jared Holz, Mizuho Securities healthcare equity strategist, joins ‘Squawk Box’ to discuss Eli Lilly’s announcement to release single-dose vials of its anti-obesity drug Zepbound, how the news will expand access to the drug, state of the obesity drug market, and more.

Share This

Latest Mizuho News

Mizuho Americas and NPower advance tech career pathways for New Yorkers through Path2TECH: NetSA

Mizuho Americas and NPower advance tech career pathways for New Yorkers through Path2TECH: NetSA

January 8, 2026
Mizuho Americas announces $1 million in grants through the Mizuho USA Foundation

Mizuho Americas announces $1 million in grants through the Mizuho USA Foundation

January 5, 2026
Nvidia is the most compelling tech stock you can buy right now, says Mizuho’s Jordan Klein

Nvidia is the most compelling tech stock you can buy right now, says Mizuho’s Jordan Klein

November 18, 2025

Mizuho news from around the globe

back-to-top-blue